Autonomic response to walk tests is useful for assessing outcome measures in people with multiple sclerosis - Kontaxis S, Laporta E, Garcia E, Guerrero AI, Zabalza A, Matteo M, Lucia R, Simblett S, Weyer J, Hotopf M, Narayan VA, Rashid Z, Folarin AA, Dobson RJB, Buron MD, Leocani L, Cummins N, Vairavan S, Costa GD, Magyari M, S ørensen PS, Nos C, Bailón R, Comi G, Consortium TRC.
OBJECTIVE: The aim of this study was to evaluate the association between changes in the autonomic control of cardiorespiratory system induced by walk tests and outcome measures in people with Multiple Sclerosis (pwMS). METHODS: Electrocardiogram (E... (Source: SafetyLit)
Source: SafetyLit - April 28, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Treatment May Delay Earliest MS Events
(MedPage Today) -- BOSTON -- Treatment with teriflunomide (Aubagio), a drug approved for relapsing multiple sclerosis (MS), reduced the risk of a clinical event in people with radiologically isolated syndrome (RIS), the phase III TERIS trial... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - April 26, 2023 Category: Neurology Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of Polivy (first-line treatment for an aggressive form of blood cancer)EU approva...
Source: Roche Investor Update - April 26, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
Basel, 26 April 2023As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of Polivy (first-line treatment for an aggressive form of blo...
Source: Roche Media News - April 26, 2023 Category: Pharmaceuticals Source Type: news
Novel MS Drug Good as Gold in Phase II Study
(MedPage Today) -- BOSTON -- Gold nanoparticles in an oral suspension helped patients with relapsing multiple sclerosis (MS) preserve ocular and overall function when added to standard medications in a phase II trial, a researcher said here... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - April 25, 2023 Category: Neurology Source Type: news
